Biowaiver monographs for immediate release solid oral dosage forms: Rifampicin
Identifieur interne : 002454 ( Istex/Curation ); précédent : 002453; suivant : 002455Biowaiver monographs for immediate release solid oral dosage forms: Rifampicin
Auteurs : C. Becker [Allemagne] ; J. B. Dressman [Allemagne] ; H. E. Junginger [Thaïlande] ; S. Kopp [Suisse] ; K. K. Midha [Canada] ; V. P. Shah [Pays-Bas] ; S. Stavchansky [États-Unis] ; D. M. Barends [Pays-Bas]Source :
- Journal of Pharmaceutical Sciences [ 0022-3549 ] ; 2009-07.
Abstract
Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of new multisource and reformulated immediate release (IR) solid oral dosage forms containing rifampicin as the only Active Pharmaceutical Ingredient (API) are reviewed. Rifampicin's solubility and permeability, its therapeutic use and index, pharmacokinetics, excipient interactions and reported BE/bioavailability (BA) problems were taken into consideration. Solubility and absolute BA data indicate that rifampicin is a BCS Class II drug. Of special concern for biowaiving is that many reports of failure of IR solid oral dosage forms of rifampicin to meet BE have been published and the reasons for these failures are yet insufficiently understood. Moreover, no reports were identified in which in vitro dissolution was shown to be predictive of nonequivalence among products. Therefore, a biowaiver based approval of rifampicin containing IR solid oral dosage forms cannot be recommended for either new multisource drug products or for major scale‐up and postapproval changes (variations) to existing drug products. © 2009 Wiley‐Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:2252–2267, 2009
Url:
DOI: 10.1002/jps.21624
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002454
Links to Exploration step
ISTEX:32253E0C22887116A6012BDF437360E2D43D6538Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Biowaiver monographs for immediate release solid oral dosage forms: Rifampicin</title><author><name sortKey="Becker, C" sort="Becker, C" uniqKey="Becker C" first="C." last="Becker">C. Becker</name><affiliation wicri:level="1"><mods:affiliation>Institute of Pharmaceutical Technology, J.W. Goethe University, Frankfurt am Main, Germany</mods:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute of Pharmaceutical Technology, J.W. Goethe University, Frankfurt am Main</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Bayer Technology Services GmbH, Leverkusen, Germany</mods:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Bayer Technology Services GmbH, Leverkusen</wicri:regionArea></affiliation></author><author><name sortKey="Dressman, J B" sort="Dressman, J B" uniqKey="Dressman J" first="J. B." last="Dressman">J. B. Dressman</name><affiliation wicri:level="1"><mods:affiliation>Institute of Pharmaceutical Technology, J.W. Goethe University, Frankfurt am Main, Germany</mods:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute of Pharmaceutical Technology, J.W. Goethe University, Frankfurt am Main</wicri:regionArea></affiliation></author><author><name sortKey="Junginger, H E" sort="Junginger, H E" uniqKey="Junginger H" first="H. E." last="Junginger">H. E. Junginger</name><affiliation wicri:level="1"><mods:affiliation>Naresuan University, Faculty of Pharmaceutical Sciences, Phitsanulok, Thailand</mods:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Naresuan University, Faculty of Pharmaceutical Sciences, Phitsanulok</wicri:regionArea></affiliation></author><author><name sortKey="Kopp, S" sort="Kopp, S" uniqKey="Kopp S" first="S." last="Kopp">S. Kopp</name><affiliation wicri:level="1"><mods:affiliation>World Health Organization, Geneva, Switzerland</mods:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>World Health Organization, Geneva</wicri:regionArea></affiliation></author><author><name sortKey="Midha, K K" sort="Midha, K K" uniqKey="Midha K" first="K. K." last="Midha">K. K. Midha</name><affiliation wicri:level="1"><mods:affiliation>University of Saskatchewan, Saskatoon, Saskatchewan, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of Saskatchewan, Saskatoon, Saskatchewan</wicri:regionArea></affiliation></author><author><name sortKey="Shah, V P" sort="Shah, V P" uniqKey="Shah V" first="V. P." last="Shah">V. P. Shah</name><affiliation wicri:level="1"><mods:affiliation>International Pharmaceutical Federation FIP, Den Haag, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>International Pharmaceutical Federation FIP, Den Haag</wicri:regionArea></affiliation></author><author><name sortKey="Stavchansky, S" sort="Stavchansky, S" uniqKey="Stavchansky S" first="S." last="Stavchansky">S. Stavchansky</name><affiliation wicri:level="2"><mods:affiliation>Division of Pharmaceutics, College of Pharmacy, University of Texas at Austin, Austin, Texas</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Division of Pharmaceutics, College of Pharmacy, University of Texas at Austin, Austin</wicri:cityArea></affiliation></author><author><name sortKey="Barends, D M" sort="Barends, D M" uniqKey="Barends D" first="D. M." last="Barends">D. M. Barends</name><affiliation wicri:level="1"><mods:affiliation>RIVM—National Institute for Public Health and the Environment, Bilthoven, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>RIVM—National Institute for Public Health and the Environment, Bilthoven</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>E-mail: dirk.barends@rivm.nl</mods:affiliation><country wicri:rule="url">Pays-Bas</country></affiliation><affiliation><mods:affiliation>Correspondence address: RIVM—National Institute for Public Health and the Environment, Bilthoven, The Netherlands. Telephone: 31 30 2744209; Fax: 31 30 2744462.</mods:affiliation><wicri:noCountry code="subField">2744462.</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:32253E0C22887116A6012BDF437360E2D43D6538</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/jps.21624</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-LDB7ZHN2-1/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002454</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002454</idno><idno type="wicri:Area/Istex/Curation">002454</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Biowaiver monographs for immediate release solid oral dosage forms: Rifampicin</title><author><name sortKey="Becker, C" sort="Becker, C" uniqKey="Becker C" first="C." last="Becker">C. Becker</name><affiliation wicri:level="1"><mods:affiliation>Institute of Pharmaceutical Technology, J.W. Goethe University, Frankfurt am Main, Germany</mods:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute of Pharmaceutical Technology, J.W. Goethe University, Frankfurt am Main</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Bayer Technology Services GmbH, Leverkusen, Germany</mods:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Bayer Technology Services GmbH, Leverkusen</wicri:regionArea></affiliation></author><author><name sortKey="Dressman, J B" sort="Dressman, J B" uniqKey="Dressman J" first="J. B." last="Dressman">J. B. Dressman</name><affiliation wicri:level="1"><mods:affiliation>Institute of Pharmaceutical Technology, J.W. Goethe University, Frankfurt am Main, Germany</mods:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute of Pharmaceutical Technology, J.W. Goethe University, Frankfurt am Main</wicri:regionArea></affiliation></author><author><name sortKey="Junginger, H E" sort="Junginger, H E" uniqKey="Junginger H" first="H. E." last="Junginger">H. E. Junginger</name><affiliation wicri:level="1"><mods:affiliation>Naresuan University, Faculty of Pharmaceutical Sciences, Phitsanulok, Thailand</mods:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Naresuan University, Faculty of Pharmaceutical Sciences, Phitsanulok</wicri:regionArea></affiliation></author><author><name sortKey="Kopp, S" sort="Kopp, S" uniqKey="Kopp S" first="S." last="Kopp">S. Kopp</name><affiliation wicri:level="1"><mods:affiliation>World Health Organization, Geneva, Switzerland</mods:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>World Health Organization, Geneva</wicri:regionArea></affiliation></author><author><name sortKey="Midha, K K" sort="Midha, K K" uniqKey="Midha K" first="K. K." last="Midha">K. K. Midha</name><affiliation wicri:level="1"><mods:affiliation>University of Saskatchewan, Saskatoon, Saskatchewan, Canada</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>University of Saskatchewan, Saskatoon, Saskatchewan</wicri:regionArea></affiliation></author><author><name sortKey="Shah, V P" sort="Shah, V P" uniqKey="Shah V" first="V. P." last="Shah">V. P. Shah</name><affiliation wicri:level="1"><mods:affiliation>International Pharmaceutical Federation FIP, Den Haag, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>International Pharmaceutical Federation FIP, Den Haag</wicri:regionArea></affiliation></author><author><name sortKey="Stavchansky, S" sort="Stavchansky, S" uniqKey="Stavchansky S" first="S." last="Stavchansky">S. Stavchansky</name><affiliation wicri:level="2"><mods:affiliation>Division of Pharmaceutics, College of Pharmacy, University of Texas at Austin, Austin, Texas</mods:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Division of Pharmaceutics, College of Pharmacy, University of Texas at Austin, Austin</wicri:cityArea></affiliation></author><author><name sortKey="Barends, D M" sort="Barends, D M" uniqKey="Barends D" first="D. M." last="Barends">D. M. Barends</name><affiliation wicri:level="1"><mods:affiliation>RIVM—National Institute for Public Health and the Environment, Bilthoven, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>RIVM—National Institute for Public Health and the Environment, Bilthoven</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>E-mail: dirk.barends@rivm.nl</mods:affiliation><country wicri:rule="url">Pays-Bas</country></affiliation><affiliation><mods:affiliation>Correspondence address: RIVM—National Institute for Public Health and the Environment, Bilthoven, The Netherlands. Telephone: 31 30 2744209; Fax: 31 30 2744462.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Pharmaceutical Sciences</title><title level="j" type="alt">JOURNAL OF PHARMACEUTICAL SCIENCES</title><idno type="ISSN">0022-3549</idno><idno type="eISSN">1520-6017</idno><imprint><biblScope unit="vol">98</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="2252">2252</biblScope><biblScope unit="page" to="2267">2267</biblScope><biblScope unit="page-count">16</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-07">2009-07</date></imprint><idno type="ISSN">0022-3549</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-3549</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of new multisource and reformulated immediate release (IR) solid oral dosage forms containing rifampicin as the only Active Pharmaceutical Ingredient (API) are reviewed. Rifampicin's solubility and permeability, its therapeutic use and index, pharmacokinetics, excipient interactions and reported BE/bioavailability (BA) problems were taken into consideration. Solubility and absolute BA data indicate that rifampicin is a BCS Class II drug. Of special concern for biowaiving is that many reports of failure of IR solid oral dosage forms of rifampicin to meet BE have been published and the reasons for these failures are yet insufficiently understood. Moreover, no reports were identified in which in vitro dissolution was shown to be predictive of nonequivalence among products. Therefore, a biowaiver based approval of rifampicin containing IR solid oral dosage forms cannot be recommended for either new multisource drug products or for major scale‐up and postapproval changes (variations) to existing drug products. © 2009 Wiley‐Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:2252–2267, 2009</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002454 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 002454 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:32253E0C22887116A6012BDF437360E2D43D6538
|texte= Biowaiver monographs for immediate release solid oral dosage forms: Rifampicin
}}
| This area was generated with Dilib version V0.6.33. |  |